Disc Medicine's Bitopertin Meets All Primary and Secondary Endpoints in Phase 3 EPP Trial

• Disc Medicine on Oct. 19, 2026, reported bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial.
• Results in erythropoietic protoporphyria showed increased pain-free time in light, fewer phototoxic reactions and improved quality of life versus placebo.
• Bitopertin was generally well tolerated, with no new safety signals; dizziness was the most common treatment-related adverse event.
• An FDA application resubmission is planned by year-end 2026, with a decision anticipated by mid-2027.
• Topline results were announced; more detailed findings will be presented at a future medical conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190700PRIMZONEFULLFEED9848066) on October 19, 2026, and is solely responsible for the information contained therein.